A Study of SHR-4394 Injection in Subjects With Prostate Cancer
NCT06783829 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 240
Last updated 2025-02-27
Summary
This is an open label, multi-center, multiple dose Phase I study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-4394 injection in subjects with prostate cancer.
Conditions
Interventions
- DRUG
-
SHR4394
SHR4394
Sponsors & Collaborators
-
Jiangsu HengRui Medicine Co., Ltd.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-01-22
- Primary Completion
- 2027-03-31
- Completion
- 2027-03-31
Countries
- China
Study Locations
More Related Trials
-
A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
NCT05009290 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
NCT06568094 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC
NCT04603833 ·Status: UNKNOWN ·Phase: PHASE2
-
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT04676607 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
NCT06139575 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
NCT03741712 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
NCT04102124 ·Status: TERMINATED ·Phase: PHASE2
-
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
NCT07163910 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
NCT06834321 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07230106 ·Status: RECRUITING ·Phase: PHASE2
-
A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer
NCT06970119 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Taxotere Prostate Cancer New Indication Registration Trial in China
NCT00436839 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase I/II Study of HE3235 in Patients With Prostate Cancer
NCT00716794 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
NCT07311694 ·Status: RECRUITING ·Phase: PHASE3
-
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
NCT03490838 ·Status: TERMINATED ·Phase: PHASE1
-
Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer
NCT03081481 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer
NCT02747342 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC
NCT04108247 ·Status: UNKNOWN ·Phase: PHASE1
-
Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer
NCT04253483 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
NCT05354375 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
NCT06809426 ·Status: COMPLETED ·Phase: NA
-
Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT
NCT05983198 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Adjuvant Chemotherapy for High Malignant Prostate Cancer
NCT06864533 ·Status: RECRUITING ·Phase: NA
-
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer
NCT06094842 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01834209 ·Status: NO_LONGER_AVAILABLE